Characteristics | All | Gal-1 | p-value | Gal-1 tumor cells | p-value | |||||||
(N = 70) | Weak (N = 22) | Strong (N = 48) | Weak (N = 24) | Strong (N = 46) | ||||||||
| No. | % | No. | % | No. | % |
| No. | % | No. | % |
|
Age (years) |
|
|
|
|
|
|
| |||||
Mean ± SD | 50.24 ± 9.58 | 49.13 ± 9.13 | 50.75 ± 9.84 | 0.265 | 50.50 ± 9.82 | 50.10 ± 9.56 | 0.848 | |||||
Median (Range) | 52.50 (27 - 62) | 50 (27 - 61) | 54 (27 - 62) | 53.50 (27 - 61) | 52 (27 - 62) | |||||||
Grade |
|
|
|
|
|
|
|
|
|
|
|
|
Low | 18 | 27.7% | 13 | 72.2% | 5 | 27.8% | <0.001‡ | 16 | 88.9% | 2 | 11.1% | <0.001‡ |
High | 52 | 74.3% | 9 | 17.3% | 43 | 82.7% | 8 | 15.4% | 44 | 84.6% | ||
LN |
|
|
|
|
|
|
|
|
|
|
|
|
Negative | 22 | 31.4% | 10 | 45.5% | 12 | 54.5% | 0.087‡ | 11 | 50% | 11 | 50% | 0.061‡ |
Positive | 48 | 68.6% | 12 | 25% | 36 | 75% | 13 | 27.1% | 35 | 72.9% | ||
Stage |
|
|
|
|
|
|
|
|
|
|
|
|
Stage I | 8 | 11.4% | 6 | 75% | 2 | 25% | 0.003§ | 5 | 62.5% | 3 | 37.5% | 0.010§ |
Stage II | 12 | 17.1% | 4 | 33.3% | 8 | 66.7% | 6 | 50% | 6 | 50% | ||
Stage III | 32 | 45.7% | 10 | 31.2% | 22 | 68.8% | 10 | 31.2% | 22 | 68.8% | ||
Stage IV | 18 | 25.7% | 2 | 11.1% | 16 | 88.9% | 3 | 16.7% | 15 | 83.3% | ||
CA125 (u/ml) |
|
|
|
|
|
|
| |||||
Mean ± SD | 1071.31 ± 666.91 | 806.77 ± 641.61 | 1192.56 ± 649.05 | 0.025 | 762.16 ± 643.79 | 132.60 ± 626.57 | 0.010 | |||||
Median (Range) | 1238.50 (69 - 2008) | 1226.50 (69 - 1965) | 1246 (76 - 2008) | 865 (69 - 2008) | 1248.50 (76 - 2005) | |||||||
Gal-1 (ng/ml) |
|
|
|
|
|
|
| |||||
Mean ± SD | 334.84 ± 187.67 | 210.04 ± 135.00 | 392.04 ± 181.47 | <0.001 | 253.41 ± 171.94 | 377.32 ± 183.07 | 0.002 | |||||
Median (Range) | 277 (32 - 763) | 173.50 (35 - 598) | 282 (32 - 763) | 263 (35 - 651) | 282 (32 - 763) | |||||||
Gal-1 |
|
|
|
|
|
|
|
|
|
|
|
|
Weak | 22 | 31.4% |
|
|
|
|
| 15 | 68.2% | 7 | 31.8% | <0.001‡ |
Strong | 48 | 68.6% |
|
|
|
| 7 | 18.8% | 39 | 81.2% | ||
Gal-1 tumor cells |
|
|
|
|
|
|
|
|
|
|
|
|
Weak | 24 | 34.3% | 15 | 62.5% | 9 | 37.5% | <0.001‡ |
|
|
|
|
|
Strong | 46 | 65.7% | 7 | 15.2% | 39 | 84.8% |
|
|
|
|